PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
14-Jul-2022 83% fewer vaccinated women hospitalised during pregnancy – but only Omicron jab can maintain success New Office for National Statistics
14-Jul-2022 Nanoform and Pharmanovia to breathe new life into iconic medicines Nanoform Finland Plc
14-Jul-2022 Grünenthal acquires testosterone treatment Nebido™ from Bayer Bayer
13-Jul-2022 Resaphene Suisse AG: FDA approval process for tinnitus therapy tinniwell continues (news with additional features) Resaphene Suisse AG
13-Jul-2022 PharmiWeb.Jobs Welcomes Excelya PharmiWeb.Jobs
13-Jul-2022 Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel Gilead Sciences
13-Jul-2022 Original-Research: MagForce AG (von GBC AG) MagForce AG
13-Jul-2022 Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate Heidelberg Pharma AG
13-Jul-2022 Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU Relief Therapeutics Holding SA
13-Jul-2022 Gerresheimer AG: Gerresheimer on track to deliver record financial year 2022 after solid second quarter Gerresheimer AG
12-Jul-2022 IGEA Pharma N.V.: IGEA PHARMA HAS ANNOUNCED THAT LMH - AN INDUSTRIAL HOLDING COMPANY - HAS COMPLETED THE DUE DILIGENCE PROCESS FOR A EURO 6.000.000 COMMITTMENT TO FUND THE SWISS CBD EXTRACTION FACILIT IGEA Pharma N.V.
12-Jul-2022 ProBioGen Teams Up with Granite Bio for Cell Line Development and GMP Manufacturing Services B3C newswire
12-Jul-2022 Vaccentis appoints Martin Munte as CEO and strengthens Board Vaccentis
12-Jul-2022 Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxis Global Newswire
12-Jul-2022 Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors Novo Nordisk
12-Jul-2022 No thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study. Novo Nordisk
12-Jul-2022 Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi Neuraxpharm
12-Jul-2022 vasopharm GmbH Announces Brain Lactate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury vasopharm GmbH
12-Jul-2022 Destiny Pharma receives award from the Cystic Fibrosis Foundation Destiny Pharma
12-Jul-2022 Adrenomed appoints David Germonpré as Chief Financial Officer Adrenomed AG